首页> 外文期刊>Retina >HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
【24h】

HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY

机译:慢性中央性浆膜性视网膜病变的半流式光动力疗法

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To evaluate the results of indocyanine green angiography (ICGA)-guided verteporfin (Visudyne?; Novartis Pharma, Switzerland) photodynamic therapy (PUT) with half-fluence rate in the treatment of chronic central serous chorioretinopathy. Methods: A retrospective review was conducted of 20 eyes of 19 consecutive patients with subfoveal fluid cause by chronic central serous chorioretinopathy with choroidal hyperpermeability on ICGA and symptoms of at least 6 months. ICGA-guided verteporfin (6 mg/m~2) PDT with half-fluence rate (25 J/cm2) was performed. ICGA findings were classified as intense, intermediate, or minimal hyperfluorescence depending on the degree of choroidal hyperpermeability. The resolution of the subretinal fluid and recurrence rates were assessed in relation to the different degrees of choroidal hyperfluorescence. Results: Best-corrected visual acuity at baseline was 40 letters (+-13; n = 20) according to the Early Treatment Diabetic Retinopathy Study chart. At 12 months after PDT, the mean best-corrected visual acuity improved to 44 letters (P < 0.01). Pretreatment central foveal thickness 325mum and decreased by a mean of 103mum at Month 12 control (P < 0.05). At Month 1 after PDT, subretinal fluid in spectral-domain optical coherence tomography was completely resolved in 100% of eyes regardless to their degree of choroidal hyperfluorescence. Two eyes of the intense hyperfluorescence group and 1 eye of the intermediate hyperfluorescence group developed recurrence of symptoms over 12 months and received another PDT with half-fluence rate within the 12-month control period. Treatment effect was not depending on the degree of choroidal hyperpermeability at baseline. No systemic side effects were observed during the 12-month follow-up. Conclusion: ICGA-guided half-fluence PDT with verteporfin is effective in treating chronic symptomatic central serous chorioretinopathy with choroidal hyperpermeability in ICGA, resulting in both visual improvement and reduction of central foveal thickness.
机译:目的:评价吲哚菁绿血管造影术(ICGA)引导的verteporfin(Visudyne ?;瑞士诺华制药)的半动态通量光动力疗法(PUT)治疗慢性中央性浆液性脉络膜视网膜病变的结果。方法:回顾性分析了19例因慢性中枢性浆液性脉络膜视网膜病变伴脉络膜通透性过高的连续性小凹下积液患者的ICGA,症状至少持续6个月。进行了ICGA引导的Verteporfin(6 mg / m〜2)PDT,半通量率(25 J / cm2)。根据脉络膜通透性高的程度,将ICGA的发现分为强烈,中度或极度过荧光。根据脉络膜过度荧光的不同程度评估视网膜下液的分辨率和复发率。结果:根据早期糖尿病视网膜病变研究图表,最佳矫正视力在基线时为40个字母(+ -13; n = 20)。 PDT后12个月,平均最佳矫正视力提高到44个字母(P <0.01)。预处理中心凹厚度为325mum,在第12个月对照组平均减少103mum(P <0.05)。在PDT后的第1个月,无论脉络膜超荧光程度如何,在100%的眼睛中,光谱域光学相干断层扫描中的视网膜下液已完全消失。强烈高荧光组的两只眼和中间高荧光组的一只眼在12个月内出现症状复发,并在12个月的控制期内接受另一次半通量的PDT。治疗效果不取决于基线时脉络膜通透性的程度。在12个月的随访中未观察到全身性副作用。结论:ICGA引导的半剂量PDT与Verteporfin可有效治疗ICGA中脉络膜通透性过高的慢性症状性中央性浆液性脉络膜视网膜病变,从而改善视力并减少中央凹的厚度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号